Clinical effectiveness and cost-effectiveness of growth hormone in children

a systematic review and economic evaluation
  • 168 Pages
  • 4.28 MB
  • 9795 Downloads
  • English

NCCHTA , Southampton
StatementJ. Bryant ... [et al.].
SeriesHealth technology assessment -- 2002 v.6, no.18
ContributionsBryant, Jackie., National Co-ordinating Centre for HTA (Great Britain), Health Technology Assessment Programme.
The Physical Object
Paginationiv, 168p. :
ID Numbers
Open LibraryOL18649442M

Download Clinical effectiveness and cost-effectiveness of growth hormone in children FB2

One comparative cohort study focused on the clinical effectiveness of hGH for sleep-related breathing disorders in PWS patients.2Polysomnography studies (PSG) were conducted to assess respiratory flow, respiratory effort, and blood oxygen saturation (ODI) to calculate an apnoea-hypopnoea index (AHI).Author: Rob Edge, Philip la Fleur, Lorna Adcock.

Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. Longer reads. Diet and cancer risk – tackling a meaty research topic; Healthy policies, healthy people; Hospital or ‘hospital at home’ – what’s best for older people?Cited by: The clinical effectiveness of GH in children was synthesised through a narrative review with full tabulation of results of all included studies.

In the economic evaluation, a cost-effectiveness model was constructed using the best available evidence to determine cost-effectiveness in a UK setting. Executive summary: Growth hormone in children.

As a model of the growth hormone (GH) dependence of growth in prepuberty and puberty, the growth of children (93 boys, 89 girls) who survived in first remission for treatment of acute. PDF | On Feb 1,J Bryant and others published Clinical effectiveness and cost-effectiveness of growth hormone in children: A systematic review and economic evaluation | Find, read and cite.

The aim of the review was to assess the clinical effectiveness and cost-effectiveness of growth hormone (GH) in children with one of five conditions: growth hormone deficiency (GHD), Turner syndrome (TS), chronic renal failure (CRF), Prader-Willi syndrome (PWS) or idiopathic short stature (ISS).

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookiesCited by: GH in Children Confidential, Submitted to NICE and HTA 12 October, CLINICAL AND COST EFFECTIVENESS OF GROWTH HORMONE IN CHILDREN.

Report commissioned by: NHS HTA Programme On behalf of: The National Institute of Clinical Excellence Produced by: Reviews Team Southampton Health Technology Assessments Centre. Significant uncertainty is therefore associated with the clinical effectiveness evidence in this report. Data on adverse events and risks of human growth hormone treatment was absent from the identified evidence on this patient population.

No cost-effectiveness evidence or relevant guidelines were identified in the limited literature search. Objective To estimate the cost-effectiveness of growth hormone (GH) therapy for idiopathic short stature (ISS).

Design Cost-effectiveness analysis. Setting Decision model. Patients A cohort of year-old prepubertal boys with ISS treated with GH.

Interventions Comparison of children treated for 5 years with GH therapy vs children receiving no by: Human Growth Hormone Treatment for Adult Growth Hormone Deficiency: A Review of the Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; Mar Two previous CADTH reports examined the clinical effectiveness of human growth hormone (hGH) for Prader-Willi Syndrome (PWS) in adolescents and adults. These reports found that treatment with hGH results in improvement in body composition in patients with Prader-Willi syndrome and summarized evidence-based guidelines for the treatment of children and adults with : Rob Edge, Philip la Fleur, Lorna Adcock.

The purpose of this report is to retrieve and review the existing evidence of clinical effectiveness, safety, and cost-effectiveness of human growth hormone replacement (GHR) therapy in patients with severe growth hormone deficiency (GHD) due to pituitary destruction 25 years of age and older.

This report also aims to retrieve and review existing guidelines for GHD due to pituitary destruction in. Human Growth Hormone Treatment for Prader-Willi Syndrome in Adolescent and Adult Patients: Clinical Evidence, Safety, and Guidelines - NCBI Bookshelf.

The purpose of this report is to review the clinical effectiveness of human growth hormone (GH) treatment for Prader-Willi syndrome (PWS) in adolescent and adult patients and the evidence based guidelines for the use of GH for treating. Human Growth Hormone: Research and Clinical Practice offers an unprecedented cutting-edge synthesis of basic science and clinical practice.

Timely and innovative, this book will benefit both basic and clinical researchers, as well as those clinical endocrinologists who want to use growth hormone not only in treating children, but also in.

The cost-effectiveness of growth hormone replacement therapy (Genotropin(R)) in hypopituitary adults in Sweden. Article (PDF Available) in Cost Effectiveness and Resource Allocation 11(1) Significant uncertainty is therefore associated with the clinical effectiveness evidence in this report.

Data on adverse events and risks of human growth hormone treatment was absent from the identified evidence on this patient population. No cost-effectiveness evidence or relevant guidelines were identified in the limited literature : Rob Edge, Philip la Fleur, Lorna Adcock.

Growth hormone fuels childhood growth and helps maintain tissues and organs throughout life. It's produced by the pea-sized pituitary gland — located at the base of the brain. Beginning in middle age, however, the pituitary gland slowly reduces the amount of growth hormone it.

To evaluate the cost-effectiveness of growth hormone (GH) treatment (Genotropin®) compared with no GH treatment in adults with GH deficiency in a Swedish societal setting. A Markov-type cost-utility simulation model was constructed and used to simulate, for men and women, morbidity and mortality for GH-treated and -untreated individuals over a year by: 6.

In fact, inthe FDA approved growth hormone (GH) to promote accelerated growth and adult height in the shortest % of children and adolescents who do not have any detectable medical problems. GH had previously been approved for treating youths with GH deficiency; in this case, medication was substituting for a hormone that these.

To investigate the influence of growth hormone (GH) on linear growth before and during puberty in children with GH analysed the relationship between pubertal growth and GH dose in a large dataset of children (n = ) with GH deficiency using multiple linear regression and multilevel modelling with repeated measures by: 4.

Get this from a library. Human growth hormone treatment for children with Prader-Willi syndrome: a review of clinical effectiveness, cost-effectiveness, and guidelines.

[Rob Edge; Philip La Fleur; Lorna Adcock; Canadian Agency for Drugs and Technologies in Health,; Canadian Agency for Drugs and Technologies in Health. Rapid Response Service,] -- Two previous CADTH reports. The somatropin trial had an initial two-year study period, with subsequent follow-ups to assess growth to adult height.

Growth hormone treatment was continued for 13 years after the initial two-year period (a total of 15 years). UK mortality was applied for each year of the model. The main clinical effectiveness estimate was the patient's height. In Human Growth Hormone: Research and Clinical Ptractice, Roy Smith and a distinguished panel of researchers and clinicians combine a review of GH regulation and its action at the molecular level with a state-of-the-art description of the basis for GH deficiency and the use of GH therapy in a variety of clinical : $   THE USE of biosynthetic growth hormone (GH) to treat children with idiopathic, familial, or constitutional short stature (hereafter referred to as idiopathic short stature) is is ongoing debate among the medical community, third-party payers, and families of affected children about the appropriateness and effectiveness of treatment.

More than 1 million children in the Cited by:   Cost effectiveness of proton versus photon radiation therapy with respect to the risk of growth hormone deficiency in children.

Description Clinical effectiveness and cost-effectiveness of growth hormone in children FB2

was provided by anthropometric reference data obtained from the Centers for Disease Control and Prevention. 21 The Red Book provided the average wholesale a previous cost‐effectiveness analysis Cited by:   HGH injections are the most effective form of human growth hormone. HGH injections may be more costly than other forms of HGH since they are legitimate and available by prescription only.

The daily cost of HGH injections may range anywhere between $5 and $82 per day and will vary based on your dosage and the HGH brand. To compare the clinical and cost-effectiveness of recombinant human growth hormone (rhGH) versus treatment without rhGH for the treatment of growth hormone disorders in children.

Searching Eleven databases (MEDLINE, EMBASE, NHS EED and BIOSIS included) were searched from inception to June for articles in English. Human growth hormone treatment is prescribed for children who have been diagnosed with growth hormone deficiency, based on a variety of symptoms and tests. Both human growth hormone treatment, and deficiency in general, can be a confusing area of the medical world.

Growth Hormones on Rise in Healthy Kids co-author of the new book, Many experts worry that there are no long-term studies on the health effects of growth hormone on healthy children.

Details Clinical effectiveness and cost-effectiveness of growth hormone in children EPUB

For treatment of growth failure caused by growth hormone deficiency: Children—Dose is based on body weight and must be determined by your doctor. The usual total weekly dose is milligram (mg) per kilogram (kg) ( mg per pound) of body weight.Cost Effectiveness of Proton Versus Photon Radiation Therapy With Respect to the Risk of Growth Hormone Deficiency in Children Raymond Mailhot Vega, MD, MPH1; Jane Kim, PhD2; Abby Hollander, MD3; Jona Hattangadi-Gluth, MD4; Jeff Michalski, MD5; Nancy J.

Tarbell, MD 6; TorunnMD ; Marc Bussiere, MSc ; and Shannon M. MacDonald, MD6 BACKGROUND: Proton therapy in Cited by: 2 Clinical need and practice Human growth hormone is produced by the anterior pituitary gland. The synthetic form is called somatropin (recombinant human growth hormone). Human growth hormone is essential for normal growth in children.